Evotec acquires compound management business from Galapagos

6/1/2011, 8:17 AM (Source: GlobeNewswire)
Evotec AG /
Evotec acquires compound management business from Galapagos
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

·         Evotec to further strengthen its integrated innovation offering with
world-class compound management
·         Synergies with Evotec's drug discovery alliance business expected
·         €12.5 Mio total purchase price for profitable business will be paid in
·         EVOTEC Revenue guidance 2011 will increase, strategic cash position
remains strong
Hamburg, Germany; Mechelen, Belgium - 1 June 2011: Evotec AG (Frankfurt Stock
Exchange: EVT; TecDAX) and Galapagos NV (Euronext: GLPG) today announced that
Evotec has acquired Compound Focus, Inc., the compound management business of
BioFocus, a Galapagos Company.
Strengthen Evotec's leadership role in drug discovery

This acquisition allows Evotec to augment its early drug discovery offering
substantially, provides critical mass to its existing compound management
offering, and adds profitable revenues. Compound Focus, Inc. is based in South
San Francisco, US and is the world leader in small molecule compound management
services. The company's technologies are focused on automated storage and custom
design solutions for small molecule drugs. The current key customer base
includes US federal institutes and pharma companies such as Elan, Lundbeck,
Sepracor or Procter & Gamble. In 2010, Compound Focus had revenues of €7.8M with
an operating profit of €2.6 m.
Transaction structure reflects value potential
For the acquisition of all shares in Compound Focus Inc. Evotec will pay
Galapagos an immediate cash upfront of €10.25 m and an additional €2.25 m in
potential earn out payments upon performance of the business in 2012/2013
depending on revenues and certain corporate milestones.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "This
acquisition will substantially improve our ability to support our alliance
partners in developing and managing their compound libraries. The link to our
industry leading screening platform further strengthens our hit identification
capabilities. In addition, the profitable revenues shown by Compound Focus over
the last years will further enhance our earnings profile going forward."
Onno van de Stolpe, Chief Executive Officer of Galapagos, commented: "Today's
transaction enables us to concentrate on what we do best in BioFocus and
Argenta, providing top class drug discovery solutions needed to deliver
molecules for our customers. Compound management is not strategic to our
offering. We are pleased to have found a good home for Compound Focus and wish
them continued success as part of Evotec."
Following this transaction, Evotec changes its revenue guidance for 2011 from
€64-66 m to €68-70 m, and Galapagos changes its revenue guidance for 2011 from
€150 m to €146 m.

With comfortably more than €55 m liquidity by the end of 2011, despite the
recently closed acquisition of Compound Focus, the strategic cash position of
Evotec remains very strong.

Burrill Merchant Banking acted as financial adviser to Galapagos.

Evotec invites you to join a conference call announcing the acquisition of
Compound Focus, Inc.

Details of the Conference Call:

Wednesday 1 June 2011 at
2.30 p.m. CET
1.30 p.m. GMT
5.30 a.m. PDT / 8.30 a.m. EDT

Dial-in Numbers:

+49 (0) 6103 485 3001 (Germany)
+44-207-153-2027 (UK)
US: +1-480-629-9673

Pass Code:  4444097

A simultaneous slide presentation for participants dialing in via phone is
available at www.equitystory.com, password: evotec 0611. You can also listen to
the conference call via audio webcast including presentation slides at

If you are unable to attend, a recording will be available for 24 hours after
the call at the following phone numbers: +49 69 58 99 90 568 (Germany),
+44 207 154 2833 (UK), +1 303 590 3030 (US). The access code is 4444097#. The
on-demand version of the webcast will be available on our website:
http://www.evotec.com - Investors/Events/Financial Calendar.

Contact Evotec AG:

Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,

Contact Galapagos:
Onno van de Stolpe, CEO, Phone: +31 6 2909 8028,ir@glpg.com

Elizabeth Goodwin, Director Investor Relations, Phone: +31 6 2291 6240,

Forward-Looking Statements

Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The forward-looking
statements contained herein represent the judgement of Evotec as of the date of
this report. Such forward-looking statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release publicly any updates
or revisions to any such statements to reflect any change in our expectations or
any change in events, conditions or circumstances on which any such statement is

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Pdf of Press release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.